Haemadipsa yanyuanensis LDTI Expansion
Lineage-specific expansion of LDTI (leech-derived tryptase inhibitor) gene family in H. yanyuanensis (Lin 2025) — candidate mast-cell modulator repertoire.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Lineage-specific expansion of LDTI (leech-derived tryptase inhibitor) gene family in H. yanyuanensis (Lin 2025) — candidate mast-cell modulator repertoire.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
This LDTI expansion is identified at the genome / transcriptome level only. Functional tryptase-inhibitor activity has not been demonstrated for the H. yanyuanensis paralogs. No FDA-approved derivative exists.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Source species
- Haemadipsa yanyuanensis
- Discovered
- 2025 · Lin Y et al.
Biological Targets
- → tryptase / mast-cell-derived serine proteases (predicted)
Key Citations
- Lin Y et al. (2025), BMC Genomics · PMID 41469844
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.